Fintel reports that on January 22, 2025, Needham initiated coverage of Absci (NasdaqGS:ABSI) with a Buy recommendation. Analyst Price Forecast Suggests 164.38% Upside As of December 23 ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...

Wednesday, Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The ...

This approach allows Absci to quickly advance and monetize clinical-stage assets, aligning well with its AI/ML-driven platform. Price Action: ABSI stock is up 23% at $3.96 at the last check on ...

VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating ...

On Friday, H.C. Wainwright maintained a positive stance on Absci Corp (NASDAQ:ABSI), with an analyst from the firm reiterating a Buy rating and a price target of $7.00. The endorsement comes after a ...

We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going to take a look at where Absci (NASDAQ:ABSI) stands against other AI ...

Across the recent three months, 7 analysts have shared their insights on Absci ABSI, expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of ...